Richard S. Levy's most recent trade in Madrigal Pharmaceuticals Inc was a trade of 6,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Nov. 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 6,000 | 4,000 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.46 per share. | 13 Nov 2025 | 6,000 | 29,697 (0%) | 0% | 16.5 | 98,760 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.36 per share. | 13 Nov 2025 | 2,500 | 23,697 (0%) | 0% | 7.4 | 18,400 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 2,500 | 2,500 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 522.70 per share. | 13 Nov 2025 | 1,434 | 22,961 (0%) | 0% | 522.7 | 749,557 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 519.67 per share. | 13 Nov 2025 | 1,355 | 25,797 (0%) | 0% | 519.7 | 704,147 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 521.79 per share. | 13 Nov 2025 | 1,094 | 24,395 (0%) | 0% | 521.8 | 570,836 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 515.64 per share. | 13 Nov 2025 | 919 | 28,632 (0%) | 0% | 515.6 | 473,876 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 518.53 per share. | 13 Nov 2025 | 835 | 27,152 (0%) | 0% | 518.5 | 432,974 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 523.66 per share. | 13 Nov 2025 | 811 | 22,150 (0%) | 0% | 523.7 | 424,687 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 517.51 per share. | 13 Nov 2025 | 645 | 27,987 (0%) | 0% | 517.5 | 333,796 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 528.60 per share. | 13 Nov 2025 | 440 | 21,237 (0%) | 0% | 528.6 | 232,586 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 520.68 per share. | 13 Nov 2025 | 308 | 25,489 (0%) | 0% | 520.7 | 160,369 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 527.85 per share. | 13 Nov 2025 | 200 | 21,677 (0%) | 0% | 527.9 | 105,570 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 524.49 per share. | 13 Nov 2025 | 153 | 21,997 (0%) | 0% | 524.5 | 80,247 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 514.67 per share. | 13 Nov 2025 | 146 | 29,551 (0%) | 0% | 514.7 | 75,142 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 526.68 per share. | 13 Nov 2025 | 120 | 21,877 (0%) | 0% | 526.7 | 63,202 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 530.20 per share. | 13 Nov 2025 | 40 | 21,197 (0%) | 0% | 530.2 | 21,208 | Common Stock |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 1,101 | 18,474 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 1,101 | 1,101 | - | - | Restricted Share Units | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2025 | 1,101 | 0 | - | - | Restricted Share Units | |
| Kodiak Sciences Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 1,290 | 1,290 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 715 | 21,197 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 16,798 | 16,798 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 3,173 | 0 | - | - | Restricted Share Units | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2025 | 3,173 | 17,373 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 2,799 | 2,799 | - | - | Restricted Share Units | |
| Protara Therapeutics Inc | Richard S. Levy | Director | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 14 May 2025 | 20,000 | 51,000 (0%) | 0% | 3.2 | 63,800 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.06 per share. | 10 Apr 2025 | 9,470 | 20,482 (0%) | 0% | 65.1 | 616,118 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2025 | 9,470 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.36 per share. | 07 Nov 2024 | 5,000 | 16,012 (0%) | 0% | 7.4 | 36,800 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 07 Nov 2024 | 5,000 | 11,012 (0%) | 0% | 350 | 1,750,000 | Common Stock |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 1,303 | 14,200 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 1,303 | 0 | - | - | Restricted Share Units | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 1,303 | 1,303 | - | - | Restricted Share Units | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.36 per share. | 01 Nov 2024 | 5,000 | 16,012 (0%) | 0% | 7.4 | 36,800 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 5,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 300.10 per share. | 01 Nov 2024 | 2,800 | 13,212 (0%) | 0% | 300.1 | 840,278 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 301.22 per share. | 01 Nov 2024 | 1,100 | 12,112 (0%) | 0% | 301.2 | 331,339 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 302.25 per share. | 01 Nov 2024 | 800 | 11,312 (0%) | 0% | 302.2 | 241,799 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 304.29 per share. | 01 Nov 2024 | 300 | 11,012 (0%) | 0% | 304.3 | 91,287 | Common Stock |
| Kodiak Sciences Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 11,012 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 19,040 | 19,040 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 4,373 | 0 | - | - | Restricted Share Units | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 4,373 | 12,897 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 3,173 | 3,173 | - | - | Restricted Share Units | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 747 | 8,524 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 747 | 747 | - | - | Restricted Share Units | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 747 | 0 | - | - | Restricted Share Units | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 111.06 per share. | 01 Apr 2024 | 6,000 | 21,298 (0%) | 0% | 111.1 | 666,360 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 5,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.36 per share. | 01 Apr 2024 | 5,000 | 15,298 (0%) | 0% | 7.4 | 36,800 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 255.90 per share. | 01 Apr 2024 | 4,387 | 16,911 (0%) | 0% | 255.9 | 1,122,629 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 256.88 per share. | 01 Apr 2024 | 3,900 | 13,011 (0%) | 0% | 256.9 | 1,001,836 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 257.94 per share. | 01 Apr 2024 | 1,600 | 11,411 (0%) | 0% | 257.9 | 412,696 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 265.28 per share. | 01 Apr 2024 | 713 | 10,598 (0%) | 0% | 265.3 | 189,145 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 267.07 per share. | 01 Apr 2024 | 300 | 10,298 (0%) | 0% | 267.1 | 80,122 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 259.07 per share. | 01 Apr 2024 | 100 | 11,311 (0%) | 0% | 259.1 | 25,907 | Common Stock |
| Kodiak Sciences Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2023 | 5,000 | 0 | - | - | Restricted Share Units | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2023 | 5,000 | 5,000 (0%) | 0% | - | Class A Common Share | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 1,198 | 10,298 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 26,236 | 26,236 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 4,373 | 4,373 | - | - | Restricted Share Units | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 17 Jan 2023 | 12,489 | 21,589 (0%) | 0% | 105.1 | 1,312,344 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 12,489 | 0 | - | - | Stock Option (Right to buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.45 per share. | 17 Jan 2023 | 10,000 | 31,589 (0%) | 0% | 100.5 | 1,004,500 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 292.68 per share. | 17 Jan 2023 | 5,227 | 20,637 (0%) | 0% | 292.7 | 1,529,838 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 294.68 per share. | 17 Jan 2023 | 5,164 | 11,925 (0%) | 0% | 294.7 | 1,521,728 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 293.54 per share. | 17 Jan 2023 | 3,548 | 17,089 (0%) | 0% | 293.5 | 1,041,480 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 291.66 per share. | 17 Jan 2023 | 3,325 | 25,864 (0%) | 0% | 291.7 | 969,770 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 295.45 per share. | 17 Jan 2023 | 2,325 | 9,600 (0%) | 0% | 295.4 | 686,921 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 290.36 per share. | 17 Jan 2023 | 1,600 | 29,189 (0%) | 0% | 290.4 | 464,576 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 296.68 per share. | 17 Jan 2023 | 500 | 9,100 (0%) | 0% | 296.7 | 148,340 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 287.08 per share. | 17 Jan 2023 | 400 | 31,089 (0%) | 0% | 287.1 | 114,832 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 288.91 per share. | 17 Jan 2023 | 300 | 30,789 (0%) | 0% | 288.9 | 86,673 | Common Stock |
| Madrigal Pharma Inc | Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 285.28 per share. | 17 Jan 2023 | 100 | 31,489 (0%) | 0% | 285.3 | 28,528 | Common Stock |
| Kodiak Sciences Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 30,000 | 30,000 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 5,000 | 5,000 | - | - | Restricted Share Units | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to buy) | |
| Protara Therapeutics Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kodiak Sciences Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 7,368 | 7,368 | - | - | Stock Option (Right to Buy) | |
| Kiniksa Pharma Ltd (Class A) | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 33,237 | 33,237 | - | - | Share Option | |
| Madrigal Pharma Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 12,489 | 12,489 | - | - | Stock Option (Right to buy) | |
| Protara Therapeutics Inc | Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) |